 "Neuland Labs zooms over 40% in two trading days")
Neuland Laboratories rallied to its record high of Rs 1,319, up 20% on the BSE in early morning trade, extending its Wednesday surge, after media report suggests that Teva Pharma made an announcement that the US Food and Drug Administration (USFDA) accepted its new drug application and granted a priority for SD-809 for treatment of tardive dyskinesia.
In past two trading days, the stock rose 44% from Rs 917 on February 28, 2017.
On clarification of on news report appeared on TV channel that US FDA grants priority review for SD-809, Neuland Laboratories said the company’s relationships with their customers both under the Custom Manufacturing Solutions (CMS) and the Generic Active Pharmaceutical Ingredients (API) manufacturing are bound by confidentially clauses.
All our communications to the exchanges and the investors in the past have bound by these agreements with our customers, it added.
The company said the approval for the aforesaid product, is not received by Neuland Laboratories and therefore the company cannot give any comments on the development.
Neuland is a no-compromise, API manufacturing service provider, offering worldwide compliant manufacturing facilities to its customers that it guarantees not to compete with in finished product.
At 11:26 am; the stock was up 16% at Rs 1,277 as compared to 0.45% rise in the S&P BSE Sensex. A combined 432,545 shares changed hands on the counter so far against an average sub 50,000 shares that were traded daily in past two weeks on both the exchanges.
In past two trading days, the stock rose 44% from Rs 917 on February 28, 2017.
On clarification of on news report appeared on TV channel that US FDA grants priority review for SD-809, Neuland Laboratories said the company’s relationships with their customers both under the Custom Manufacturing Solutions (CMS) and the Generic Active Pharmaceutical Ingredients (API) manufacturing are bound by confidentially clauses.
All our communications to the exchanges and the investors in the past have bound by these agreements with our customers, it added.
The company said the approval for the aforesaid product, is not received by Neuland Laboratories and therefore the company cannot give any comments on the development.
Neuland is a no-compromise, API manufacturing service provider, offering worldwide compliant manufacturing facilities to its customers that it guarantees not to compete with in finished product.
At 11:26 am; the stock was up 16% at Rs 1,277 as compared to 0.45% rise in the S&P BSE Sensex. A combined 432,545 shares changed hands on the counter so far against an average sub 50,000 shares that were traded daily in past two weeks on both the exchanges.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%